Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group

Cancer

Volumn 92, Issue 10, 2001, Pages 2699-2708

  Goto, Shoko ^a,b   Umehara, Shunsuke ^a,b   Gerbing, Robert B ^b   Stram, Daniel O ^a   Brodeur, Garrett M ^c   Seeger, Robert C ^a   Lukens, John N ^d   Matthay, Katherine K ^e   Shimada, Hiroyuki ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age; Biology; Differentiation; Histopathology; International Neuroblastoma Pathology Classification; Mitosis karyorrhexis index; MYCN; Neuroblastic tumors; Prognosis

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CELL DIFFERENTIATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE AMPLIFICATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MITOSIS; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GANGLIONEUROBLASTOMA; GANGLIONEUROMA; GENE AMPLIFICATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035889955     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011115)92:10<2699::AID-CNCR1624>3.0.CO;2-A     Document Type: Article

References (48)

1. In-situ neuroblastoma: Its contribution to the natural history of neural crest tumors
2. Nerve growth factor
3. Naturally occurring cell death during neuronal development
4. History of the discovery of neuronal death in embryos
5. Complete pathologic maturation and regression of Stage IVS neuroblastoma without treatment
6. N-myc genomic content and DNA ploidy in Stage IVS neuroblastoma
7. A natural immune system in pregnancy serum lethal to human neuroblastoma cells: A possible mechanism of spontaneous regression
8. Expression of nerve growth factor receptor mRNAs and clinical response to retinoic acid in neuroblastoma
9. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?
10. Natural course of neuroblastoma detected by mass screening: A 5-year prospective study at a single institution
11. Excellent outcome of Stage II neuroblastoma is independent of residual disease and radiation therapy
12. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma
13. Successful treatment of Stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group study
14. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
15. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
16. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
17. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients
18. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study
19. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells
20. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line
21. The biological effects of antisense N-myc expression in human neuroblastoma
22. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis
23. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: Function and regulation
24. Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee
25. The International Neuroblastoma Pathology Classification (the Shimada system)
26. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas
27. International Neuroblastoma Pathology Classification for prognostic evaluation of patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group
28. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cic-retinoic acid
29. Favorable biology and outcome of Stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study
30. Biologic variables in the outcome of Stages I and II neuroblastoma treated with surgery as primary therapy: A Children's Cancer Group study
31. Biologic factors determine prognosis in infants with Stage IV neuroblastoma: A prospective the Children's Cancer Group study
32. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene
33. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction
34. Prognostic importance of serum ferritin in patients with Stage III and IV neuroblastoma: The Children's Cancer Study Group experience
35. A proposed staging for children with neuroblastoma
36. Evidence for molecular heterogeneity in human ganglioneuroblastoma
37. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular
38. Nonparametric estimation from incomplete observations
39. Regression models
40. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group study
41. Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc
42. Myc and Max proteins possess distinct transcriptional activities
43. MYC oncogenes and human neoplastic disease
44. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma
45. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN
46. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification
47. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma
48. Splicing pattern of the high affinity nerve growth factorreceptor (trkA) transcript in neuroblastomas: Correlationwith histopathology and clinical outcome